Download to read offline
More Related Content
Similar to Investment_Mapping_v7_web for pharmas manu
Investment_Mapping_v7_web for pharmas manu
- 1.
- 2. Afrigen South Africanhub + Biovac Institute Pasteur Tunis - Tunisia BioGeneric Pharma – Egypt TBD - Kenya nstitute Pasteur Dakar - Senegal Biovaccines - Nigeria end-to-end Spokes & Current industrial initiatives for Covid-19 vaccines in Africa Fill&Finish mRNA plans to 3rd parties mRNA spokes Algeria Morocco Ghana Uganda Rwanda Source: CHAI and UNICEF Botswana mRNA vaccine production Kenya Moderna Moderna and Kenya signed a MoU to build mRNA facility Rwanda Senegal, South Africa BioNTech BioNTech announced a plan to develop the capacity to produce upcoming mRNA-based vaccines Ghana BioNTech BioNTech to establish manufacturing plants for fill, finish and packaging Other Industrial Partnerships Algeria Saidal & Sinovac 200M capacity, started in 2021, then move up the value chain Saidal & Gamaleya Sputnik V starting Sept 2021 ($40M capacity) Sothema & Sinopharm $60M capacity South Africa Aspen & J&J F&F started in 2021. 2022 plan to manufacture under Aspen’s brand name NantSA & Immunity Bio To set up a new plant to produce vaccines Rubic Consortium & Dyadic & WITS to establish a new plant Biovac & Pfizer started a tech transfer in 2021 for AU member states Egypt Eva Pharma EgyVax currently under Ph 1 Vacsera & Sinovac Produced ~30M doses of Sinovac vaccine Minipharma & Gamaleya To produce 40M doses per year Botswana NantWorks to establish a new plant and to produce Corbevax by 2026
- 3. Financial &Technical contributionsto African vaccine local production outside of the mRNA Tech Transfer Hub Institution Content of the support AFD Granted €1.8M to IPD for a feasibility study Afreximbank To support infrastructural facilities and initiate vaccine production in Ogun State, Nigeria for €180M Belgium €4.5M for NRA strengthening in Senegal and €0,5M to Rwanda Germany BMZ (KfW) granted €20M to IPD’s MADIBA project and €1M to develop vaccine production capacity BMZ (GIZ) committed €5M to Ghana to advance local manufacturing + 0.18M +€2.7M co-financing from EU to strengthen the FDA BMZ (GIZ) committed €11.7M for establishing a local vaccine in Rwanda and €24M to support EAC Centre of Excellence for vaccine DEG support to Aspen with €144M (J&J vaccine) €51M to South Africa to support vaccination campaigns and the development of a vaccine supply chain (incl. regulatory strengthening) €10M to support ACDC and promote regulatory framework €250M promotional loan to Afreximbank + €12.2M to the prep4vac project Institution Content of the support FCDO FCDO supported the business case development and feasibility assessment for Aspen and IPD IFC coalition IPD €13M grant for MADIBA project Rwanda and Morocco to conduct diagnostic and feasibility studies Biovac to raise €136M Aspen contracted €644M loan Team Europe & EU IPD received €6.7M to support the MADIBA project Granted €3.1M to Rwanda US Gov US DFC granted €2.9M to IPD to support the MADIBA project Aspen received €181M to produce J&J vaccine for the African continent World Bank Attributed Granted €27M to Biovaccines for vaccine manufacturing plant
- 4. Spokes & currentindustrial initiatives for Covid-19 vaccines in Latin America Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End Argentina - Sinergium Biotech Brazil – Bio-Manguinho Venezuela Peru Mexico Cuba mRNA vaccine production Brazil HDT Bio & SENAI CIMATEC HDT Bio granted to SENAI CIMATEC a non-exclusive license to produce its RNA vaccine Eurofarma & BioNtech to produce 100M doses Other Industrial Partnerships Argentina Richmond Lab & Gamaleya Research Institute to produce Sputnik mAbxience & AstraZeneca mAbxience to produce AstraZeneca’s drug substance to be FF in Mexico Sinergium & Sinopharm to produce 1M doses /week Brazil Fiocruz & AstraZeneca for 100.4M doses capacity Biomm & CanSino to distribute the vaccine in Brazil UniĂŁo QuĂmica & Gamaleya to set up FF capacity Instituto Butantan & Sinovac to produce 1M doses Cuba BioCubaFarma developed Abdala and Soberana 2 vaccine Mexico Birmex & Gamaleya Birmex & AstraZeneca Peru Plans to build a plant in 2023 to produce Sputnik V and other vaccines Venezuela Espromed-Bio & Center for Genetic Engineering and Biotechnology Espromed-Bio to produce 4M doses from the Center for Genetic Engineering and Biotechnology
- 5. Source: CHAI andUNICEF Pakistan - National Institute of Health Vietnam - Polyvac Bangladesh – Incepta Indonesia - Biofarma Malaysia Sri Lanka Philippines Thailand mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End mRNA vaccine production Bangladesh Globe Biotech to develop its own mRNA vaccines. Under Ph1 Thailand Bionet consortium composed of Pennsylvania, North Carolina, California- Davis, Chulalongkorn, IVI. Currently under Ph 2 CT Vietnam Vinbiocare & Arcturus Other Industrial Partnerships Bangladesh Incepta to produce Corbevax Incepta & Sinopharme MoU to produce 5M doses Indonesia Bio Farma & Children’s Hospital to produce Texas Children’s Hospital’ vaccine Bio Farma & Sinovac Malaysia Pharmaniaga & Sinovac to distribute then produce 14M doses Solution Biologic & Cansino Philippines Glovax Biotech & Eubiologics to produce 40M doses Sri Lanka State Pharmaceutical Corporation & Sinovac to produce 9M doses Thailand Siam Bioscience & AstraZeneca Vietnam IVAC stops Ph 3 CT of its COVIVAC due to volunteer shortages IVAC & CIGB to produce Cuban Abdala vaccine Nanogen to develop a recombinant vaccine that is still under Ph 3 trial Vabiotech & Gamaleya Vabiotech& Shionogi AIC & Shionogi Polyvac & Gamaleya
- 6. Current industrial initiativesfor Covid-19 vaccines in India Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End Drug substance mRNA vaccine production Gennova Gennova Gennova is developing mRNA vaccine Other Industrial Partnerships Biological E Biological E & Texas Children’s Hospital Biological E & J&J Biological E & J&J to collaborate to produce 600M doses/year Serum Institute of India SII & Novavax SII & Gamaleya Research Institute SII & AstraZeneca Bharat Biotech Bharat Biotech To develop an inactivated vaccine Bharat Biotech & Haffkine Bharat Biotech to licence Haffkine Bharat Biotech & Indian Immunologicals Bharat Biotech to licence Indian Immunologicals Bharat Biotech & Hester Biosciences Bharat Biotech & Hester Biosciences to sign a CDMO Panacea CEPI support the development of multi-epitope, nanoparticle-based vaccine candidates Gamaleya Gamaleya & Gland Pharma To produce 252M doses Gamaleya & Hetero Biopharma Gamaleya & Morepen Laboratories Gamaleya & Panacea Biotec Collaboration discharged Gamaleya & Stelis Pharma To produce 900M doses Gamaleya & Virchow Biotech Gamaleya & Wockhardt
- 7. Current industrial initiativesfor Covid-19 vaccines in China Source: CHAI and UNICEF mRNA spokes mRNA plans to 3rd parties Fill&Finish End to End mRNA vaccine development CSPC ZhongQi Under Ph 2 CT Fosun Pharma & BioNtech China yet to approve BioNtech vaccine Walvax Got approval in Indonesia Everest Medicines & Providence License agreement to produce Covid-19 and other vaccines Stemirna Therapeutics To develop then produce up to 400M doses Sinopharm To wait approval to initiate Ph1 CT CR Pharma & Everest Medicines To establish the company “mRNA&Co” focused on vaccines discovery CanSino Under Ph 3 CT Suzhou Abogen Biosciences Under Ph 1 CT AIM Vaccine Under Ph 3 CT Wuhan Recogen Biotechnology Under Ph 1 CT Other Industrial Partnerships & production Anhui Zhifei Longcom Under Ph 3 CT CanSino Sinovac Sinopharm Institute of Medical Biology of the Chinese Academy of Medical Sciences To produce between 500M and 1 billions doses Shanghai Zerun Bio & Walvax CEPI support to develop COVID-19 multi-variant vaccine Poly Pharm & Celsion To produce DNA based vaccine Advaccine & Inovio To produce DNA based vaccine BioKangtai & AztraZeneca Rhodiola Bacterin & Gamaleya Shenzhen Yuanxing Gene-tech & Gamaleya To produce 60M doses TopRidge Pharma & Gamaleya Hualan Biological Bacterin & Gamaleya To produce 100M doses